147 related articles for article (PubMed ID: 10392325)
21. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers.
Wong YN; Simcoe D; Hartman LN; Laughton WB; King SP; McCormick GC; Grebow PE
J Clin Pharmacol; 1999 Jan; 39(1):30-40. PubMed ID: 9987698
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and pharmacodynamics of the ETA-selective endothelin receptor antagonist SPP301 in healthy human subjects.
Dieterle W; Mann J; Kutz K
J Clin Pharmacol; 2004 Jan; 44(1):59-66. PubMed ID: 14681342
[TBL] [Abstract][Full Text] [Related]
24. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
Kisicki JC; Fiske K; Lyne A
Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
[TBL] [Abstract][Full Text] [Related]
25. Macitentan: entry-into-humans study with a new endothelin receptor antagonist.
Sidharta PN; van Giersbergen PL; Halabi A; Dingemanse J
Eur J Clin Pharmacol; 2011 Oct; 67(10):977-84. PubMed ID: 21541781
[TBL] [Abstract][Full Text] [Related]
26. Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects.
van Giersbergen PL; Dingemanse J
J Clin Pharmacol; 2005 Jan; 45(1):42-7. PubMed ID: 15601804
[TBL] [Abstract][Full Text] [Related]
27. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Martin DE; Blum R; Doto J; Galbraith H; Ballow C
Clin Pharmacokinet; 2007; 46(7):589-98. PubMed ID: 17596104
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and pharmacodynamics of avitriptan during intravenous administration in healthy subjects.
Sharma A; Jusko WJ; Fulmor IE; Norton J; Uderman HD; Salazar DE
J Clin Pharmacol; 1999 Jul; 39(7):685-94. PubMed ID: 10392323
[TBL] [Abstract][Full Text] [Related]
29. Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.
van Giersbergen PL; Popescu G; Bodin F; Dingemanse J
J Clin Pharmacol; 2003 Jan; 43(1):15-22. PubMed ID: 12520623
[TBL] [Abstract][Full Text] [Related]
30. Bosentan for the treatment of pulmonary arterial hypertension.
Kenyon KW; Nappi JM
Ann Pharmacother; 2003; 37(7-8):1055-62. PubMed ID: 12841819
[TBL] [Abstract][Full Text] [Related]
31. A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3.
Berger RMF; Gehin M; Beghetti M; Ivy D; Kusic-Pajic A; Cornelisse P; Grill S; Bonnet D;
Br J Clin Pharmacol; 2017 Aug; 83(8):1734-1744. PubMed ID: 28213957
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects.
Müller P; Flesch G; de Gasparo M; Gasparini M; Howald H
Eur J Clin Pharmacol; 1997; 52(6):441-9. PubMed ID: 9342579
[TBL] [Abstract][Full Text] [Related]
33. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist.
van Giersbergen PL; Dingemanse J
Eur J Clin Pharmacol; 2007 Feb; 63(2):151-8. PubMed ID: 16636870
[TBL] [Abstract][Full Text] [Related]
34. Protection against aspirin-induced human gastric mucosal injury by bosentan, a new endothelin-1 receptor antagonist.
Duggan AE; Stack W; Hull M; Filipowicz B; Knifton A; Crome R; Weber C; Bishop A; Polak J; Hawkey CJ
Aliment Pharmacol Ther; 1999 May; 13(5):631-5. PubMed ID: 10233186
[TBL] [Abstract][Full Text] [Related]
35. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
[TBL] [Abstract][Full Text] [Related]
36. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans.
Sütsch G; Bertel O; Kiowski W
Cardiovasc Drugs Ther; 1997 Jan; 10(6):717-25. PubMed ID: 9110115
[TBL] [Abstract][Full Text] [Related]
37. Endothelin antagonism with bosentan: current status and future perspectives.
Ono K; Matsumori A
Cardiovasc Drug Rev; 2002; 20(1):1-18. PubMed ID: 12070530
[TBL] [Abstract][Full Text] [Related]
38. Endothelin receptors blockade blunts hypoxia-induced increase in PAP in humans.
Pham I; Wuerzner G; Richalet JP; Peyrard S; Azizi M
Eur J Clin Invest; 2010 Mar; 40(3):195-202. PubMed ID: 20415698
[TBL] [Abstract][Full Text] [Related]
39. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers.
Jung J; Choi S; Cho SH; Ghim JL; Hwang A; Kim U; Kim BS; Koguchi A; Miyoshi S; Okabe H; Bae KS; Lim HS
Clin Ther; 2010 Jun; 32(6):1178-87. PubMed ID: 20637970
[TBL] [Abstract][Full Text] [Related]
40. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A.
Binet I; Wallnöfer A; Weber C; Jones R; Thiel G
Kidney Int; 2000 Jan; 57(1):224-31. PubMed ID: 10620203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
